nature portfolio

Corresponding author(s):	Witold Surewicz
Last updated by author(s):	Aug 2, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~ .					
St	· 2	Ť١	IS:	ŀι	C^{ς}

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware and code
Poli	cy information about <u>availability of computer code</u>
Da	ata collection AFM images were collected by NanoScope 9.1. Automated cryo-EM data collection was driven by SerialEM 3.7.14

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Cryo-EM data were processed by RELION 3.1, MotionCor2 1.2.2, CTFFIND 4.1.13. The atomic model was built and refined by Coot 0.8.9.2 and

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

PHENIX 1.18. Figures of density map and atomic model were prepared in UCSF Chimera 1.14.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Cryo-EM density map and the atomic models of human PrP23-144 fibrils have been deposited to the Electron Microscopy Data Bank and Protein data bank with the accession codes EMD-24514 and 7RL4, respectively. Those for mouse PrP23-144 fibrils have been deposited with the accession codes EMD-27458 and 8DJA. Coordinates used in structure comparison are available at the Protein Data Bank with accession code 6UUR, 7LNA, 6LNI, and 7DWV. All main data supporting the findings of this study are available within the article, Extended Data and Supplementary Information.

_	•		1			C·			100		
H	IP	\Box	-5	ne	ו א	fic	re	nc	rti	กร	J
		ı U		\sim	- 01	110	1	\sim	'	יוי.	7

Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.						
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences						
For a reference copy of t	For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>						
Life scier	nces study design						
All studies must dis	close on these points even when the disclosure is negative.						
Sample size	The final cryo-EM density map of huPrP23-144 amyloid fibrils results from 46,803 particles. The final cryo-EM density map of moPrP23-144 amyloid fibrils (polymorph 1) results from 10,628 particles. The sample size was determined by the ability to reach an overall resolution better than 4.0 Å to ensure confidence in conclusions drawn from the data.						
Data exclusions	In cryo-EM analysis of huPrP23-144 amyloid fibrils, 1,089,468 particles were extracted from the raw data and those that did not contribute to a high-resolution 3D density map were discarded. 46,803 were used in the final reconstruction. In cryo-EM analysis of moPrP23-144 amyloid fibrils, 585,965 particles were extracted from the raw data and those that did not contribute to a high-resolution 3D density map were discarded. 10,628 were used in the final reconstruction of polymorph 1 amyloid fibrils.						
Replication	Identical fibril morphologies were observed in at least five independent sample preparations. High-resolution cryo-EM analysis was performed on one sample for each fibril type.						
Randomization	Randomization was used only for the Fourier-shell correlation analysis in Extended data Fig. 2 and Extended data Fig. 5f. Randomization serves no purpose in other analysis, since no experimental groups were involved.						
Blinding	Blinding was not used because this is a study of molecular structure. No subjective assessments of group of categories were involved. Blinding would serve no purpose.						

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a Involved in the study		
\boxtimes	Antibodies	ChIP-seq		
\boxtimes	Eukaryotic cell lines	Flow cytometry		
\boxtimes	Palaeontology and archaeology	MRI-based neuroimaging		
\boxtimes	Animals and other organisms			
\boxtimes	Human research participants			
\boxtimes	Clinical data			
\boxtimes	Dual use research of concern			